Title: Pharmacotherapy for Primary Biliary Cholangitis: An Assessment of Medication
Candidacy and Rates of Treatment
Version: 5 Date: 10 Nov 2023
Reviewer's report:
In their revised version, in my opinion the authors did not provide lacking informations  to
draw firm conclusions. Among patients who were not taking UDCA, there were patients on
OCA monotherapy due to intolerance of UDCA, however reasons for UDCA intolerance are
not reported as well as which dose was not tolerated and there were 16 patients who were either
not on therapy for UDCA ("due to poor adherence, lack of follow-up, never prescribed, etc.")
or there was inadequate documentation to confirm whether their PBC had ever been treated.”
Moreover,  it was not possible to follow patients in order to assess their response to treatment,
thus the factors that may affect this were not considered in data analysis and patients with
autoimmune hepatitis/PBC overlap syndrome were not excluded. Even if the use of UDCA is
indicated in PBC/AIH overlap patients, this is a different clinical entity potentially affecting the
results of the study.
Title: Pharmacotherapy for Primary Biliary Cholangitis: An Assessment of Medication
Candidacy and Rates of Treatment
Version: 5 Date: 10 Nov 2023
Reviewer's report:
In their revised version, in my opinion the authors did not provide lacking informations  to
draw firm conclusions. Among patients who were not taking UDCA, there were patients on
OCA monotherapy due to intolerance of UDCA, however reasons for UDCA intolerance are
not reported as well as which dose was not tolerated and there were 16 patients who were either
not on therapy for UDCA ("due to poor adherence, lack of follow-up, never prescribed, etc.")
or there was inadequate documentation to confirm whether their PBC had ever been treated.”
Moreover,  it was not possible to follow patients in order to assess their response to treatment,
thus the factors that may affect this were not considered in data analysis and patients with
autoimmune hepatitis/PBC overlap syndrome were not excluded. Even if the use of UDCA is
indicated in PBC/AIH overlap patients, this is a different clinical entity potentially affecting the
results of the study.
Please review this paper.
user
Title: Pharmacotherapy for Primary Biliary Cholangitis: An Assessment of Medication
Candidacy and Rates of Treatment
Version: 5 Date: 10 Nov 2023
Reviewer's report:
In their revised version, in my opinion the authors did not provide lacking informations  to
draw firm conclusions. Among patients who were not taking UDCA, there were patients on
OCA monotherapy due to intolerance of UDCA, however reasons for UDCA intolerance are
not reported as well as which dose was not tolerated and there were 16 patients who were either
not on therapy for UDCA ("due to poor adherence, lack of follow-up, never prescribed, etc.")
or there was inadequate documentation to confirm whether their PBC had ever been treated.”
Moreover,  it was not possible to follow patients in order to assess their response to treatment,
thus the factors that may affect this were not considered in data analysis and patients with
autoimmune hepatitis/PBC overlap syndrome were not excluded. Even if the use of UDCA is
indicated in PBC/AIH overlap patients, this is a different clinical entity potentially affecting the
results of the study.
assistant